Stallergenes Greer

London, United Kingdom Founded: 2013 • Age: 13 yrs Listed Acquired By Waypoint Capital
Allergen immunotherapies for respiratory allergies are developed.

About Stallergenes Greer

Stallergenes Greer is a Healthcare company based in London (United Kingdom) founded in 2013, and was acquired by Waypoint Capital in March 2019. Allergen immunotherapies for respiratory allergies are developed. Stallergenes Greer has completed 1 acquisition, including Adeo Health Science. Its chief executive, as recorded, is Michele Antonelli. Its website stallergenesgreer.com draws about 13 thousand monthly visits. Stallergenes Greer offers products and services including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Prophylactic. Its legal entity is STALLERGENES GREER LTD.

Company details

Stallergenes Greer is developing allergen immunotherapy (vaccine) for respiratory allergies. Its drug pipeline STAGR 320 (HDM) for Allergic Rhinitis (Phase 3 in EuropeUS and approved in Japan) and for HDM) Allergic Asthma (Phase 2); STAGR 120 for (Jap.Cedar) Allergic Rhinitis (Phase 2); JPSTAGR SAIL SLIT(Ragweed) Allergic Rhinitis (Phase 3)

  • Headquarters London, United Kingdom
  • Stage Acquired
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website stallergenesgreer.com
  • Social LinkedIn X Facebook YouTube
  • Acquired by Waypoint Capital (Mar 2019)
  • Legal Name Stallergenes Greer Ltd
  • Date of Incorporation 06 Dec, 2013
  • Jurisdiction LONDON, UNITED KINGDOM
Key Metrics

Products & Services of Stallergenes Greer

Stallergenes Greer offers a comprehensive portfolio of products and services, including Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine.

Allergen Immunotherapy
Treatment

Therapy to desensitize patients against allergens for better allergy control.

Diagnosis Solutions
Diagnostic Tools

Methods for identifying allergens in respiratory and food allergies.

Precision Medicine
Personalized Therapy

Tailored treatments addressing unmet needs in allergy care globally.

Apps and channels of Stallergenes Greer

its YouTube channel Stallergenes Greer has 1.46K subscribers and 30 videos.

Stallergenes Greer
YouTube 1.46K subscribers 30 videos Science & Technology
Open channel

Videos from Stallergenes Greer

The most watched videos on Stallergenes Greer's YouTube channel, Stallergenes Greer (1.46K subscribers). Click a video to play it here.

The precision Lea deserves
41.4K views
Laboratoire de développement pharmaceutique
3K views
Stallergenes Greer lab-scale pharmaceutical development
1.4K views
Allergy, we take it personally.
1.1K views

More on Stallergenes Greer.

Investors in Stallergenes Greer

Stallergenes Greer has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include B-FLEXION.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
B-FLEXION is recognized as a private entrepreneurial investment firm.
waypointcapital.net
Premium access

Investor details for Stallergenes Greer

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Stallergenes Greer

61 people are tracked at Stallergenes Greer (21 in leadership, 2 in board & advisors, 38 in team).

NameRoleGroup
Michele Antonelli
CEOLeadership
Nicola Lamacchia
Chief Financial OfficerLeadership
Tibor Nemes
EVP, Head of AmericasLeadership
Adam Haithcox
Director, Business SystemsLeadership
Andy Möckel
Vice President Commercial Operations D-a-ch Region/ Geschäftsführer D-a-ch RegionLeadership
Christian Doering
Director Pharmaceutical Operations (dach)Leadership
Marc Valentin
Director Market Access DACH & Eu/international RegionLeadership
Jennifer Hryniw
General ManagerLeadership
Melissa A. Schmidt
Vice President, Legal And People Ops AmericasLeadership
Stefania Sara Biolcati
Finance Director South Europe (italy, Spain & Portugal)Leadership
Matthew Elfeldt
Vice President Of Commercial OperationsLeadership
Trace Little
Director Of ProcurementLeadership
Stephane Lebarbier
Global Head Of ProcurementLeadership
William Mahoney
Vice President, Global Strategic SourcingLeadership
Nicole Carfagnini
Head Of Marketing (us) - Food AllergyLeadership
Jacques Dysli
Global Head Of Performance & PortfolioLeadership
Marek Borovsky
General ManagerLeadership
Catherine Kress
VP CommunicationsLeadership
Stephanie Lauchet
Global PMO DirectorLeadership
Alexandra Hess
Head Of Site ControllingLeadership

41 more people are available in the full profile.

Premium access

Complete people profiles for Stallergenes Greer

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Stallergenes Greer

Stallergenes Greer has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Adeo Health Science.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Manufactures proprietary baby food to safely introduce eight allergens.
adeohealth.comBoston, United States2017May 2019••••
Premium access

Complete acquisition details for Stallergenes Greer

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Stallergenes Greer

5 dated milestones of Stallergenes Greer across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Stallergenes Greer is founded.
  2. Exit Acquired by Waypoint Capital.
  3. IPO Lists on the stock exchange (IPO).
  4. Exit Acquired by Waypoint Capital.
  5. Acquisition Acquires Adeo Health Science.

Web traffic of Stallergenes Greer

The website of Stallergenes Greer (stallergenesgreer.com) receives about 13.4K visits a month and ranks #1,596,150 among all websites worldwide, #2,149 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    13.4K

    ▼ 8.9% vs previous month

  • Unique visitors
    5.9K

    per month

  • Global rank
    #1,596,150

    among all websites

  • Category rank
    #2,149

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Stallergenes Greer. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
alk.net
100%
43.7K#855,421View details
mein-allergie-portal.com
mein-allergie-portal.com
64%
#455,429–
daab.de
54%
74.6K#477,513View details
stagrallergy.com
stagrallergy.com
29%
#4,744,016–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Stallergenes Greer

Premium access

Complete news archive for Stallergenes Greer

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Stallergenes Greer

Stallergenes Greer was founded in 2013.

Stallergenes Greer is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

Michele Antonelli is the CEO of Stallergenes Greer, as recorded in our data.

Stallergenes Greer is developing allergen immunotherapy (vaccine) for respiratory allergies. Its drug pipeline STAGR 320 (HDM) for Allergic Rhinitis (Phase 3 in EuropeUS and approved in Japan) and for HDM) Allergic Asthma (Phase 2); STAGR 120 for (Jap.Cedar) Allergic Rhinitis (Phase 2); JPSTAGR SAIL SLIT(Ragweed) Allergic Rhinitis (Phase 3).

Stallergenes Greer offers Allergen Immunotherapy, Diagnosis Solutions, and Precision Medicine.

Stallergenes Greer has made 1 acquisition, including Adeo Health Science.

Stallergenes Greer has 1 investor. Key investors include B-FLEXION.

Stallergenes Greer operates through Stallergenes Greer Ltd.

Yes. Stallergenes Greer was acquired by Waypoint Capital in March 2019.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available